Future studies can investigate the potential use of the other three cytokines and chemokines identified in the present study as plasma biomarkers (i.e., CXCL1, CXCL2, CCL3), all of which showed strong correlation with CCM lesion size. This evidence concerns the gene CCL3 and cerebral cavernous malformation.